- Post-Doctoral: Cancer Biology, University of California, San Francisco.
- PhD: Yale University School of Medicine.
- BA: University of California, Berkeley.
- Byron SA, Min E, Thal TS, Tapia C, Hostetter G, Watanabe A, Azorsa D, Little TH, and Kim S. (2012) Attenuation of NF-kappa B by the ING4 tumor suppressor in breast cancer. PLoS One 7(10):e46823.
- Tapia C, Zlobec I, Schneider S, Kilic E, Guth U, Bubendorf L, and Kim S. (2011) Deletion of the ING4 tumor suppressor gene is prevalent in HER2-positive breast cancer. Human Pathology 42(7): 983-90.
- Kim, S., Welm, A.L., and Bishop, J.M. (2010). A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis. Cancer Res 70:5155-5162
- Kim, S. (2005). HuntING4 New Tumor Suppressors. Cell Cycle 4(4):516-7.
- Welm, A.L., Kim, S., Welm, B.E., and Bishop, J.M. (2005). MET and MYC cooperate in mammary tumorigenesis. Proc Natl Acad Sci U S A 102(12):4324-9.
For a complete listing of Dr. Kim's publications, search PubMed.
Cancer; Diseases of development and aging; Developmental, cell and molecular biology; Gene environment interactions and epigenetics; Signaling and steroid biology
We investigate tumor suppressor (TS) genes in cancer and how TS deficiencies lead to tumor formation and progression. We have characterized Inhibitor of Growth 4 (ING4) TS in breast cancer, of which deficiency is correlated with metastatic and therapy-resistant tumors. We have defined ING4 as a transcriptional regulator that plays a critical role in tumor-immune modulation and hormone response. Ongoing studies include the molecular mechanism of ING4 and TSs in neuroblastoma and lung cancer.